title: Loss of EGF-dependent cell proliferation ability on radioresistant cell HepG2-8960-R.
abstract: Acquired radioresistance of cancer cells interferes with radiotherapy and increases the probability of cancer recurrence. HepG2-8960-R, which is one of several clinically relevant radioresistant (CRR) cell lines, has a high tolerance to the repeated clinically relevant doses of X-ray radiation. In this study, HepG2-8960-R had slightly lower cell proliferation ability than HepG2 in the presence of FBS. In particular, epidermal growth factor (EGF) hardly enhanced cell proliferation and DNA synthesis in HepG2-8960-R. Additionally, EGF could not induce the activation of Erk1/2, because the expression of EGF receptor (EGFR) protein decreased in HepG2-8960-R in accordance with the methylation of the EGFR promoter region. Therefore, cetuximab did not inhibit HepG2-8960-R cell proliferation. Our study showed that HepG2-8960-R had radioresistant and cetuximab-resistant abilities.
authors: Department of Radiopharmacy, Tohoku Pharmaceutical University, Sendai, Miyagi, Japan.
authors: Yohei
authors: Y
authors: Saito
authors: Ryo
authors: R
authors: Abiko
authors: Akira
authors: A
authors: Kishida
authors: Yoshikazu
authors: Y
authors: Kuwahara
authors: Yumi
authors: Y
authors: Yamamoto
authors: Fumihiko
authors: F
authors: Yamamoto
authors: Manabu
authors: M
authors: Fukumoto
authors: Yasuhito
authors: Y
authors: Ohkubo
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy*; D049109:Cell Proliferation / Q000187:drug effects; D000068818:Cetuximab; D004815:Epidermal Growth Factor / Q000378:metabolism*; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008745:Methylation; D011401:Promoter Regions, Genetic; D011836:Radiation Tolerance
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004815:Epidermal Growth Factor; D000068818:Cetuximab
keywords: cetuximab; hepatocellular carcinoma; radiation; radioresistance